🧠AI AnalysisPeptide Immunotherapy Shows Promise in Pediatric Peanut Allergy Trial
A phase II clinical trial indicates that a novel peptide-based monthly shot, PVX108, may safely reduce peanut allergy symptoms in children over a 12-month period.
🧠AI AnalysisA phase II clinical trial indicates that a novel peptide-based monthly shot, PVX108, may safely reduce peanut allergy symptoms in children over a 12-month period.
🔬ResearchNew intranasal and sublingual epinephrine delivery methods are demonstrating faster absorption and effectiveness in mid-stage clinical trials compared to traditional auto…
🧠AI AnalysisNew research presented at the American College of Allergy, Asthma and Immunology annual meeting reveals that nearly 40% of pediatric biologic prescriptions needing prior …
🧠AI AnalysisA 15-year-old boy experienced anaphylaxis after consuming an energy drink containing cod-derived fish collagen, highlighting potential gaps in standard allergy testing.
🔬ResearchA case series presented at the ACAAI annual meeting suggests that the biologic drug omalizumab may help eliminate anaphylaxis risks in patients with red meat allergies, t…
🥗NutritionNew research reveals that many healthcare providers continue to order broad food allergy panels despite knowing they frequently yield false positives and go against curre…
🥗NutritionResearch indicates that non-English-speaking families may face barriers in receiving early infant peanut introduction guidance, potentially missing out on allergy prevent…
🥗NutritionRecent research presented at the American College of Allergy, Asthma and Immunology indicates that the biologic drug omalizumab may help protect individuals suffering fro…
🧠AI AnalysisRecent research highlights how eosinophilic esophagitis can mimic food allergies, leading to repeated emergency visits and delayed diagnoses. Two new studies examine the …
Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.